Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press13110.17650/1726-9776-2013-9-3-96-104CLINICAL CASEКЛИНИЧЕСКИЙ СЛУЧАЙPROSTATECTOMY FOR METASTATIC PROSTATE CANCER: A CLINICAL CASEКЛИНИЧЕСКИЙ СЛУЧАЙ: ПРОСТАТЭКТОМИЯ ПРИ МЕТАСТАТИЧЕСКОМ РАКЕ ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫShirokoradV. I.ШирокорадВ. И.
Russian Federation
Shirokorad@bk.ruMoscow City Cancer Hospital Sixty-TwoМосковская городская онкологическая больница № 623009201393961042807201428072014https://oncourology.abvpress.ru/oncur/article/view/131

The paper describes a clinical case of treatment and follow-up in a prostate cancer patient with very unfavorable baseline prognosis, bone metastases, and good clinical outcome.

Приведено описание клинического случая лечения и наблюдения пациента с раком предстательной железы при крайне неблагоприятном исходном прогнозе, наличии костных метастазов с хорошим клиническим результатом.

prostate cancerbone metastasesprostatectomyрак предстательной железыметастазы в костипростатэктомия1. Каприн А.Д., Старинский В.В., Петрова Г.В. Состояние онкологической помощи населению России в 2012 году. М., 2013. С. 4, 128, 132, 136.Каприн А.Д., Старинский В.В., Петрова Г.В. Состояние онкологической помощи населению России в 2012 году. М., 2013. С. 4, 128, 132, 136.2. Ward J.F., Slezak J.M., Blute M.L. et al. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostatespecific antigen testing: 15-year outcome. BJU Int 2005;95(6):751–6. http://www.ncbi.nlm.nih.gov/ pubmed/15794776.Ward J.F., Slezak J.M., Blute M.L. et al. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostatespecific antigen testing: 15-year outcome. BJU Int 2005;95(6):751–6. http://www.ncbi.nlm.nih.gov/ pubmed/15794776.3. Joniau S., Hsu C.Y., Lerut E. et al. A pretreatment table for the prediction of final histopathology after radical prostatectomy in clinical unilateral T3a prostate cancer. Eur Urol 2007;51(2):388–96. http://www.ncbi.nlm.nih.gov/pubmed/16901622.Joniau S., Hsu C.Y., Lerut E. et al. A pretreatment table for the prediction of final histopathology after radical prostatectomy in clinical unilateral T3a prostate cancer. Eur Urol 2007;51(2):388–96. http://www.ncbi.nlm.nih.gov/pubmed/16901622.4. Yossepowitch O., Eggener S.E., Bianco F.J. Jr et al. Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods. J Urol 2007;178(2):493–9; discussion 499. http:// www.ncbi.nlm.nih.gov/pubmed/17561152.Yossepowitch O., Eggener S.E., Bianco F.J. Jr et al. Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods. J Urol 2007;178(2):493–9; discussion 499. http:// www.ncbi.nlm.nih.gov/pubmed/17561152.5. D ’Amico A.V., Whittington R., Malkowicz S.B. et al. Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer. J Clin Oncol 1999;17(1):168–72. http://www.ncbi.nlm.nih.gov/pubmed/10458230.D ’Amico A.V., Whittington R., Malkowicz S.B. et al. Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer. J Clin Oncol 1999;17(1):168–72. http://www.ncbi.nlm.nih.gov/pubmed/10458230.6. Tiguert L.L., Harrel F., Fradet Y. Disease outcome of patients with a PSA >20 treated by radical prostatectomy: analysis of 177 patients. J Urol 2006;175:311A. http://www.ncbi.nlm.nih.gov/pubmed/17561152.Tiguert L.L., Harrel F., Fradet Y. Disease outcome of patients with a PSA >20 treated by radical prostatectomy: analysis of 177 patients. J Urol 2006;175:311A. http://www.ncbi.nlm.nih.gov/pubmed/17561152.7. Inman B.A., Davies J.D., Rangel L.J. et al. Long-term outcomes of radical prostatectomy with multimodal adjuvant therapy in men with a preoperative serum prostate-specific antigen level >or = 50 ng/mL. Cancer 2008;113(7):1544–51. http://www.ncbi.nlm.nih.gov/pubmed/18680171.Inman B.A., Davies J.D., Rangel L.J. et al. Long-term outcomes of radical prostatectomy with multimodal adjuvant therapy in men with a preoperative serum prostate-specific antigen level >or = 50 ng/mL. Cancer 2008;113(7):1544–51. http://www.ncbi.nlm.nih.gov/pubmed/18680171.8. Van Poppel H., Joniau S. An analysis of radical prostatectomy in advanced stage and high-grade prostate cancer. Eur Urol 2008;53(2):253–9. http://www.ncbi.nlm.nih.gov/pubmed/17949893.Van Poppel H., Joniau S. An analysis of radical prostatectomy in advanced stage and high-grade prostate cancer. Eur Urol 2008;53(2):253–9. http://www.ncbi.nlm.nih.gov/pubmed/17949893.9. Briganti A., Chun F.K., Salonia A. et al. Validation of a nomogram predicting the probability of lymph node invasion based on the extent of pelvic lymphadenectomy in patients with clinically localized prostate cancer. BJU Int 2006;98(4):788–93. http://www.ncbi.nlm.nih. gov/pubmed/16796698.Briganti A., Chun F.K., Salonia A. et al. Validation of a nomogram predicting the probability of lymph node invasion based on the extent of pelvic lymphadenectomy in patients with clinically localized prostate cancer. BJU Int 2006;98(4):788–93. http://www.ncbi.nlm.nih. gov/pubmed/16796698.10. Ghavamian R., Bergstralh E.J., Blute M.L. et al. Radical retropubic prostatectomy plus orchiectomy versus orchiectomy alone for pTxN+ prostate cancer: a matched comparison. J Urol 1999;161(4):1223–7; discussion 1277–8. http://www.ncbi.nlm.nih.gov/pubmed/10081874.Ghavamian R., Bergstralh E.J., Blute M.L. et al. Radical retropubic prostatectomy plus orchiectomy versus orchiectomy alone for pTxN+ prostate cancer: a matched comparison. J Urol 1999;161(4):1223–7; discussion 1277–8. http://www.ncbi.nlm.nih.gov/pubmed/10081874.11. Messing E.M., Manola J., Yao J. et al. Eastern Cooperative Oncology Group study EST 3886. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 2006;7(6):472–9. http://www.ncbi.nlm.nih.gov/pubmed/16750497.Messing E.M., Manola J., Yao J. et al. Eastern Cooperative Oncology Group study EST 3886. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 2006;7(6):472–9. http://www.ncbi.nlm.nih.gov/pubmed/16750497.12. Engel J., Bastian P.J., Baur H. et al. Survival benefit of radical prostatectomy in lymph node-positive patients with prostate cancer. Eur Urol 2010. print://www.ncbi.nlm.nih.gov/ pubmed/20106588.Engel J., Bastian P.J., Baur H. et al. Survival benefit of radical prostatectomy in lymph node-positive patients with prostate cancer. Eur Urol 2010. print://www.ncbi.nlm.nih.gov/ pubmed/20106588.13. Briganti A., Karnes J.R., da Pozzo L.F. et al. Two positive nodes represent a significant cut-off value for cancer specific survival in patients with node positive prostate cancer. A new proposal based on a two-institution experience on 703 consecutive N+ patients treated with radical prostatectomy, extended pelvic lymph node dissection and adjuvant therapy. Eur Urol 2009;55(2):261–70. http://www.ncbi.nlm.nih.gov/pubmed/18838212.Briganti A., Karnes J.R., da Pozzo L.F. et al. Two positive nodes represent a significant cut-off value for cancer specific survival in patients with node positive prostate cancer. A new proposal based on a two-institution experience on 703 consecutive N+ patients treated with radical prostatectomy, extended pelvic lymph node dissection and adjuvant therapy. Eur Urol 2009;55(2):261–70. http://www.ncbi.nlm.nih.gov/pubmed/18838212.14. Schumacher M.C., Burkhard F.C., Thalmann G.N. et al. Good outcome for patients with few lymph node metastases after radical retropubic prostatectomy. Eur Urol 2008;54(2):344–52. http://www.ncbi.nlm.nih.gov/pubmed/18511183.Schumacher M.C., Burkhard F.C., Thalmann G.N. et al. Good outcome for patients with few lymph node metastases after radical retropubic prostatectomy. Eur Urol 2008;54(2):344–52. http://www.ncbi.nlm.nih.gov/pubmed/18511183.15. Johnstone P.A., Ward K.C., Goodman M. et al. Radical prostatectomy for clinical T4 prostate cancer. Cancer 2006;106:2603–9. http://www.ncbi.nlm.nih.gov/pubmed/16700037.Johnstone P.A., Ward K.C., Goodman M. et al. Radical prostatectomy for clinical T4 prostate cancer. Cancer 2006;106:2603–9. http://www.ncbi.nlm.nih.gov/pubmed/16700037.16. Gontero P., Marchioro G., Pisani R. et al. Is radical prostatectomy feasible in all cases of locally advanced non-bone metastatic prostate cancer? Results of a single-institution study. Eur Urol 2007;51(4):922–9; discussion 929–30. http://www.ncbi.nlm.nih.gov/pubmed/17049718.Gontero P., Marchioro G., Pisani R. et al. Is radical prostatectomy feasible in all cases of locally advanced non-bone metastatic prostate cancer? Results of a single-institution study. Eur Urol 2007;51(4):922–9; discussion 929–30. http://www.ncbi.nlm.nih.gov/pubmed/17049718.17. Vallett B.S. Radical perineal prostatectomy subsequent to bilateral orchiectomy. Delaware Med J 1944;16:19–20.Vallett B.S. Radical perineal prostatectomy subsequent to bilateral orchiectomy. Delaware Med J 1944;16:19–20.18. McLeod D.G., Iversen P., See W.A. et al. Casodex Early Prostate Cancer Trialists’ Group. Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer. BJU Int 2006;97(2):247–54. http://www.ncbi.nlm.nih.gov/pubmed/16430622.McLeod D.G., Iversen P., See W.A. et al. Casodex Early Prostate Cancer Trialists’ Group. Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer. BJU Int 2006;97(2):247–54. http://www.ncbi.nlm.nih.gov/pubmed/16430622.19. Messing E.M., Manola J., Yao J. et al. Eastern Cooperative Oncology Group study EST 3886. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 2006;7(6):472–9. http://www.ncbi.nlm.nih.gov/pubmed/ 16750497.Messing E.M., Manola J., Yao J. et al. Eastern Cooperative Oncology Group study EST 3886. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 2006;7(6):472–9. http://www.ncbi.nlm.nih.gov/pubmed/ 16750497.